Charles River Laboratories News and Resources

Charles River Laboratories has announced the launch of its Charles River Incubator Program (CIP), aimed at helping early-stage biotechnology companies navigate the discovery, development, and manufacturing of advanced therapies. The program, part of the company’s Global Innovation Center of Excellence,

FibroBiologics and Charles River Laboratories have entered a master services agreement to develop and manufacture FibroBiologics’ fibroblast-based therapeutic product, CYWC628. This product is set to be used in a diabetic foot ulcer (DFU) clinical trial scheduled to begin in 2025.

Charles River Laboratories International, Inc. has announced a partnership with the FOXG1 Research Foundation (FRF) to advance drug development for FOXG1 syndrome through the clinical phase. This agreement is part of a comprehensive gene therapy contract development and manufacturing organization

Charles River Laboratories International Inc. and the Gates Institute at the University of Colorado Anschutz Medical Campus have entered into a contract development and manufacturing organization (CDMO) agreement. This partnership will see Gates Institute leveraging Charles River’s expertise in cell

Charles River Laboratories, a global provider of products and services to accelerate the research, drug discovery, and drug development process, has announced a new program to develop an inhalation toxicology test. This initiative aims to reduce the reliance on traditional

Charles River Laboratories and Sanofi unveil their Virtual Control Groups (VCG) initiative. This collaboration marks a step towards reducing animal usage in research, aligning with the goals of Charles River’s Alternative Methods Advancement Project (AMAP). A VCG is a digitally created

Charles River Laboratories has launched two new frameworks for viral vector technology transfer, named Modular and Fast Track. These frameworks are designed to facilitate the continuity of product development through a seamless process transfer to the company’s Maryland-based viral vector

Charles River Laboratories has announced a contract development and manufacturing organisation (CDMO) collaboration with Axovia Therapeutics Ltd. The collaboration will see Charles River manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for

Charles River Laboratories International, Inc. and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, have announced a Good Manufacturing Practice (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement. Ship of Theseus is developing a proprietary